IL33 and Alzheimer disease: Additionally, we revealed the underlying mechanism of butyrate in regulating IL-33 and provided evidences supporting butyrate as a potential therapeutic agent for controlling inflammatory skin conditions exacerbated by S. aureus infection in AD patients.